TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Suspected metastatic renal cell carcinoma (AJCC Stage IV) with intact primary tumor~* No previous therapy for metastatic renal cell carcinoma~* Measurable disease (RECIST criteria)~* Primary tumor greater than or equal to 7cm on CT or MRI~* ECOG performance status 0-1~* At least 18 years old~* Life expectancy \> 3 months~* Adequate cardiac function (NYHA I-II)~* Not pregnant~* Provide written informed consent~* Absence of multiple liver metastases, brain or threatening bone metastases (axial skeleton and/or pathological features)~* Planned complete nephrectomy~Exclusion Criteria:~* History of primary or secondary immunodeficiency, or patients using systemic corticosteroids or cyclosporin A~* Other cancer (including renal cell carcinoma) within the last five years (with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin)~* Embolization of the renal artery prior to nephrectomy~* Active, uncontrolled infection or other serious medical illnesses, preventing study completion, in the opinion of the Principal Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Active seasonal allergic rhinitis~* Initiating first-time treatment with fluticasone furoate nasal spray (FFNS)~* Received treatment with at least one intra-nasal steroid (INS) other than FFNS during the last allergy season~* Received treatment with one or more antihistamines, leukotriene receptor atagonists (LTRA), topical ocular medications, or any over the counter (OTC) medication for allergic rhinitis symptoms during the last allergy season~* At least 18 years of age at the time of study enrollment~* Able to read, comprehend, and record information in English~* Have provided an appropriately signed and dated informed consent~Exclusion Criteria:~* Received prior treatment with FFNS~* Pregnant~* Employee or family members of an employee of the study sponsor, retail pharmacy chain, or convenient care clinic implementing the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- New prescription for fluticasone furoate nasal spray (Type: None): patients receiving their first prescription for fluticasone furoate nasal spray and who have active seasonal allergic rhinitis with a history of using another intranasal steriod (INS) and other concomitant allergic rhinitis medications to treat their seasonal allergy symptoms.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Incisional Hernia After Elective Open Abdominal Aortic Aneurysm (AAA) Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient scheduled for elective or early elective open repair of aortic aneurysm~Exclusion Criteria:~* Emergency surgery~* EVAR (endovascular procedure)~* Patients with previous midline laparotomy~* Patients with in situ abdominal mesh after previous hernia repair~* Patients with large diastasis of abdominal wall~* Allergy to penicillin~* Women before menopause (mesh can interfere with potential future pregnancies)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mesh implantation (Type: EXPERIMENTAL): Ultrapro® Mesh implantation
- Standard wound closure without a mesh (Type: ACTIVE_COMPARATOR): Standard wound closure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect of AVE0657 in Cheynes-Stokes Breathing Syndrome Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of Congestive heart failure (CHF) defined as ejection fraction ≤40% by history of echocardiography data and New York heart Association (NYHA) class II-III and of typical cyclic crescendo and decrescendo change in breathing amplitude AHI ≥10 and \<60 and majority of the apneas to be ≥60% central in origin.~Exclusion Criteria:~* Subject on supplemental oxygen~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dose Level 1 (Type: EXPERIMENTAL): None
- Dose Level 2 (Type: EXPERIMENTAL): None
- Dose Level 3 (Type: EXPERIMENTAL): None
- Dose Level 4 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): 12 subjects: 3 subjects per dose level

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Post-extubation Dysphagia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria (patients):~* age \> 18 years~* informed consent~* extubated after endotracheal intubation for more than 5 days~* Richmond Agitation-Sedation Scale (RASS) between -2 and 2~* able to sit right up~* no respiratory insufficiency/failure (for this study defined as oxygen saturation (SpO2) \< 92% with a minimum of 3 L nasal oxygen)~Inclusion Criteria (healthy subjects):~* age \> 18 years~* informed consent~Exclusion Criteria (both patients and healthy subjects):~* pre-existing dysphagia (according to medical record and screening)~* tracheostomy or previous tracheostomy~* history of prior intubation \< 3 months ago~* head/neck surgery, head/neck radiation or head/neck disease~* pre-existent esophageal disorder~* coagulopathy (thrombocytes \< 50\*10\^9 /l, or prothrombin time (PT)/activated partial thromboplastin time (APTT) \> 1.5 times the reference value, or fibrinogen \< 1000 mg/l, or use of therapeutic anticoagulant drugs)~* allergy for xylometazoline (only in case its use is indicated)~* known pregnancy~* known G6PD deficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy subjects (Type: None): Healthy subjects
- Patients (Type: None): Patients extubated after \> 5 days of mechanical ventilation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Abnormal Respiratory Mechanics and Assisted Mechanical Ventilation on Neuro-regulation of Respiration

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Man ;~* Less than 35 years old ;~* Non obese (BMI \<30 kg/m2) ;~* Normal pulmonary function tests (vital capacity and forced expiratory volume in one second in the normal range for the age and size)~* No history of respiratory disease (asthma, pneumothorax) ;~* No contraindication for nasogastric tube placement~Exclusion Criteria:~* Active or past respiratory disease ;~* Contraindication to nasogastric tube placement ;~* Less than 18 years old;~* Subject protected by the law (eg subject incapable of discernment, wardship subject, ...) ;~* Subject not covered by a social security system ;~* Subject with a subordination relationship with a member of the research team.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Study (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult trauma patients admitted to the emergency department at the University of Alabama at Birmingham (UAB) Hospital~* Blunt or penetrating injury~* UAB highest trauma activation~Exclusion Criteria:~* Age \< 19 years of age~* Patients with known bleeding diathesis or who are concurrently taking anticoagulant medication~* Patients with known liver disease~* Minor patients~* Pregnant patients (known or suspected pregnancy)~* Patients who are incarcerated~* Patients who lack a surrogate

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamins C and E (Type: EXPERIMENTAL): Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
- 0.9% saline and sugar pill (Type: PLACEBO_COMPARATOR): 100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study of the Safety and Efficacy of a Wearable Device (CLS UF) That Delivers Continuous Administration of Glucose to Recirculated Peritoneal Dialysis Fluid for the Purpose of Ultrafiltration in Patients With Congestive Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patient, 18-80 years of age.~* Prevalent PD patients with CHF with cardio-renal syndrome type II, on stable ultrafiltration, for more than two months, treated with PD based UF according to German national guidelines.~  * Therapy resistance of pharmacologic therapy: resistant hypervolemia with ascites, pleural fluid and pulmonary edema~ * Recurrent hospitalization with cardiac decompensation, ≥ 2 occasions during the last six months~ * Isolated failure of the right heart chamber~* Treatment based on night time APD therapy combined with a day time long dwell.~* Obtained written consent to participate in the study.~Exclusion Criteria:~* End stage renal disease requiring dialysis.~* Malignant disease.~* On-going infection.~* Diabetes mellitus.~* HIV and/or hepatitis positive.~* Pregnancy.~* Breastfeeding women.~* Participation in other clinical trials within one month before inclusion.~* Abdominal hernia.~* Cardiac diseases other than left ventricular heart failure, biventricular heart failure or isolated right heart chamber failure, with volume overload.~* Any immune deficiency.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Device: CLS UF (Type: EXPERIMENTAL): The purpose of CLS UF is ultrafiltration and drain of excess fluid in patients with congestive heart failure. The function of the device is to extra corporeally recirculate profiled glucose based PD fluid in a system and maintain glucose levels by adding extra glucose, to an adjustable and constant level, in order to maintain a stable ultrafiltration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients (age ≥18 years) who are diagnosed with CP-CML, AP-CML, BP-CML, or Ph+ ALL~2. Patients who are initiating Iclusig therapy for the first time, or for whom Iclusig therapy was initiated within 30 days before registry enrollment.~3. The decision to prescribe Iclusig must have been made prior to enrollment in the registry and based upon approved US indications.~4. Patients who have the ability to understand the requirements of the registry, and provide written informed consent to comply with the registry data collection procedures.~Exclusion Criteria:~1. Patients previously treated with investigational Iclusig.~2. Patients receiving any investigational agent (eg, any drug or biologic agent or medicaldevice that has not received approval in the US) or receiving Iclusig for any indication not currently approved in the US.~3. Concurrent treatment with another TKI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pioglitazone Therapy for Chronic Granulomatous Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age：1 months to 18 years~2. Chronic Granulomatous Disease~3. with severe infections~Exclusion Criteria:~1. \> 18 years of age~2. infections are treatable by conventional therapy (antibiotics, antimycotics, allogeneic granulocytes)

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone (Type: EXPERIMENTAL): Treatment for chronic granulomatous disease patients with severe infection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Natural History Study of Children With Metachromatic Leukodystrophy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of MLD by both:~   * arylsulfatase A (ASA) deficiency by assay in leukocytes AND~  * elevated sulfatide in urine~2. Appearance of the first symptoms of disease at or before 30 months of age.~3. A GMFM-88 total (percent) score greater than or equal to 40 at the screening examination.~4. The patient is less than 12 years of age at the time of enrollment.~5. The patient and his/her parent or legally authorized representative(s) must have the ability to comply with the clinical protocol.~6. Patient's parent or legally authorized representative(s) must provide written informed consent prior to performing any study-related activities. Study-related activities are any procedures that would not have been performed during normal management of the patient.~Exclusion Criteria:~1. History of hematopoietic stem cell transplantation.~2. The patient has any known or suspected hypersensitivity to agents used for anesthesia or is thought to be at an unacceptably high risk for associated potential complications of airway compromise or other conditions.~3. Any other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the study.~4. The patient is enrolled in another clinical study that involves the use of any investigational product (drug or device) within 30 days prior to study enrollment or at any time during the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- No treatment (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation of Metrological Properties of Lymphoqol

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary lymphedema, stage 2 or 3 ISL~Exclusion Criteria:~* Primary lymphedema stage 1, secondary lymphedema, Minimum 6 years, maximum 25

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: IM Olanzapine Versus Haloperidol or Midazolam

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Emergency Department patients, requiring parenteral drug sedation (as determined by an emergency clinician) will be enrolled.~Exclusion Criteria:~* Patients will be excluded if there are~  1. known hypersensitivity or contraindication to the study drugs~ 2. reversible aetiology for agitation (e.g. hypotension, hypoxia, hypoglycaemia)~ 3. known pregnancy~ 4. acute alcohol withdrawal~ 5. patients aged\>75 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: EXPERIMENTAL): intramuscular olanzapine injection (zyprexa), 5 mg/dose, first dose and an optional second dose.
- Haloperidol (Type: ACTIVE_COMPARATOR): intramuscular haloperidol injection, 5 mg/dose, first dose and an optional second dose.
- Midazolam (Type: ACTIVE_COMPARATOR): intramuscular midazolam injection, 5 mg/dose, first dose and an optional second dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of OTO-104 in Subjects With Unilateral Meniere's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria includes, but is not limited to:~* Subject has a diagnosis of unilateral Meniere's disease by 1995 American Academy of Otolaryngology - Head and Neck Surgery (AAOHNS) criteria and reports active vertigo for the 2 months prior to the study lead-in period.~* Subject has experienced active vertigo during the lead-in period.~* Subject has documented asymmetric sensorineural hearing loss.~* Subject agrees to maintain their current treatments for Meniere's disease while on-study.~Exclusion Criteria includes, but is not limited to:~* Subject is pregnant or lactating.~* Subject has a history of immunodeficiency disease.~* Subject has a history of previous endolymphatic sac surgery.~* Subject has a history of previous use of intratympanic (IT) gentamicin in the affected ear.~* Subject has a history of tympanostomy tubes with evidence of perforation or lack of closure.~* Subject has experienced an adverse reaction to IT injection of steroids.~* Subject has used an investigational drug or device in the 3 months prior to screening.~* Subject has previously been randomized to a trial of OTO-104.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- OTO-104 (Type: EXPERIMENTAL): 12 mg dexamethasone
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy